Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ZUPREME-2 (obesity + T2D)

ZUPREME-2 (obesity + T2D)

Petrelintide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Petrelintide
Population
t2d
Phase
2
Duration
28 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
petrelintide, highest doset2d28—−9.2 % vs −2.0 %
Δ −7.2 pp
—−0.7 vs +0.2——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (2)
  • petrelintide, highest dose · weight_eff · company announcement
    Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
  • petrelintide, highest dose · hba1c · company announcement
    At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ZUPREME-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.